ABSTRACT
Until long-term ongoing trials show that screening for prostate cancer Is beneficial and cost-effective, physicians should focus screening efforts on high-risk patients most likely to benefit from treatment, and inform patients about the pluses and minuses of current screening, diagnostic, and treatment methods.
- Copyright © 1998 The Cleveland Clinic Foundation. All Rights Reserved.